ReviewFoods (Basel, Switzerland)2026
1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement.
Review in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gut microbiota dysbiosis is implicated in diverse intestinal and systemic disorders, and prebiotics offer a practical strategy to modify host-microbe interactions. This review evaluates 1-kestose as a candidate precision bioactive component by integrating its chemical structure, enzymatic production, gastrointestinal fate, GH32-dependent microbial utilization, human evidence, and qPCR-based response monitoring. Many commercial fructooligosaccharides contain molecules with different degrees of polymerization, complicating structure-function interpretation. In contrast, 1-kestose is a high-purity trisaccharide fructooligosaccharide and the shortest member of the inulin-type fructans. By comparing 1-kestose with long-chain inulin, we examine how fructan chain length may influence colonic fermentation kinetics, substrate availability, and tolerability. We then discuss the role of GH32 substrate specificity in the selective microbial utilization of 1-kestose and related fructooligosaccharides, particularly by bifidobacteria and representative butyrate producers. Next, we review the mechanistic rationale and preclinical evidence for co-administration of 1-kestose and long-chain inulin. Human intervention studies have evaluated 1-kestose across gastrointestinal, metabolic, immune-related, neonatal, oncological, and bowel-habit contexts, with emerging evidence of potential benefits. One healthy-adult trial has also evaluated co-administration with long-chain inulin, although direct comparative trials remain an important future priority. Finally, we propose a research framework that integrates high-purity 1-kestose, GH32-dependent microbial selectivity, and qPCR-based baseline stratification and response monitoring. Prospective, independently replicated trials are needed to establish clinical effectiveness and determine the value of biomarker-guided intervention and combination strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.